Bioreactor Systems for MSC Therapies: Overview

Bioreactors are transforming how mesenchymal stem cells (MSCs) are produced for therapies. Here's why they matter:

• Scaling Up Production: MSCs are rare in bone marrow, and a single therapy needs 100–150 million cells. Bioreactors enable efficient, high-volume expansion compared to manual flask methods.
• Automation: Bioreactors create controlled environments (temperature, pH, oxygen) and reduce manual labor, contamination risks, and space needs.
• Efficiency: Systems like Quantum® and Scinus can expand millions of cells in days, with consistent quality and fewer steps.

Types:

• Stirred-Tank: High scalability but risks shear damage to cells.
• Rocking-Motion: Gentle on cells but less scalable.
• Hollow Fiber: Compact with high surface area but costly.
• Fixed-Bed: Protects cells but can have nutrient gradients.
• Parallel Plate: Familiar growth setup but labor-intensive for large-scale use.

Key Factors:

• Oxygen & Nutrients: Proper delivery prevents cell damage and supports growth.
• Shear Stress: Managed forces can improve cell behavior without harm.

Clinical Use:

• Systems are chosen based on therapy type (autologous vs. allogeneic), production scale, and regulatory needs. Advances like spheroid culture and bead-to-bead transfer improve efficiency and quality.

Bioreactors are essential for making MSC therapies scalable, cost-effective, and consistent, meeting the growing demand in regenerative medicine.

Types of Bioreactor Systems for MSC Expansion

Bioreactors are generally divided into two categories based on how they move cells and nutrients: mechanically driven and hydraulically driven systems. Each type has its own approach to creating an environment that supports cell growth and nutrient distribution.

Mechanically Driven Bioreactors

These systems rely on physical movement - such as stirring, rocking, or rotating - to keep cells suspended and nutrients evenly distributed in the culture medium. Cells typically adhere to microcarriers that are mixed within the medium.

Stirred-Tank Bioreactors (STRs) use a central impeller to continuously agitate the medium. This ensures uniform conditions throughout the vessel and prevents nutrient gradients. These systems are available in sizes ranging from 0.5 L to 6,000 L in single-use formats. Microcarriers used in these systems, usually 100–300 microns in diameter, offer a surface-to-volume ratio of 30 cm²/cm³, which is significantly higher than the 3 cm²/cm³ provided by traditional T-flasks.

However, STRs face a challenge with hydrodynamic shear stress. Since MSCs lack protective cell walls, they are vulnerable to damage from the mechanical forces generated by the impeller. Shear forces can reach up to 2.5 N m⁻², which can affect cell viability. Despite this drawback, STRs are widely used for large-scale allogeneic production due to their effective monitoring capabilities and ability to maintain consistent conditions across large volumes.

Rocking-Motion Bioreactors, often referred to as Wave bioreactors, take a gentler approach. A rocking platform creates wave-like fluid motion, which reduces the mechanical stress seen with impellers. The Xuri Cell Expansion System W25 by Cytiva is a well-known example. When tested with umbilical cord MSCs on CultiSpher-S microcarriers in a 2 L cell bag, this system achieved expansion factors ranging from 12.3 to 24.8, without compromising cell quality or differentiation potential.

Rotating Bed Bioreactors provide another alternative, using rotation to maintain a homogeneous cell suspension while minimizing shear stress. The Scinus Cell Expansion System is a notable example. A 2019 study in the Journal of Translational Medicine reported that this system expanded MSCs on dissolvable microcarriers over six days. Starting with 20 million cells, it produced an average of 324 million cells (ranging from 222–510 million), equating to 4.0 population doublings compared to 5.0 in flasks and 3.3 in spinner flasks.

Hydraulically driven systems, on the other hand, use continuous medium flow to support MSC expansion while keeping cells stationary.

Hydraulically Driven Bioreactors

In these systems, the culture medium flows across or through stationary cells, which are attached to fixed surfaces, fibers, or matrices. This approach minimizes direct hydrodynamic shear, protecting the cells.

Hollow Fiber Bioreactors mimic the body's natural capillary systems by using thousands of semi-permeable capillaries. Cells grow on or around these fibers while nutrients are continuously supplied through perfusion. The Quantum Cell Expansion System from Terumo BCT is a leading example, with over 25 experimental studies validating its efficacy as of 2024. One study, published in Stem Cell Reviews and Reports in November 2024, showed that a seven-day expansion of 20 million bone marrow-derived MSCs in this system yielded between 100 and 276 million cells. Importantly, the cells retained their immunomodulatory functions. This system has been applied in clinical trials for conditions like graft-versus-host disease (GVHD), Parkinson's disease, and ischemic heart disease.

Fixed-Bed (Packed-Bed) Bioreactors immobilize cells on a stationary matrix made of macrocarriers or fibers. The medium flows through the bed, delivering nutrients while protecting cells from mechanical forces. This design supports high cell density and closely resembles in vivo conditions. However, nutrient and oxygen gradients can develop within the bed, and monitoring cells directly becomes more difficult.

Parallel Plate Bioreactors, like the Corning CellCube system, consist of stacked plates where the medium recirculates across the surfaces. These systems can scale up to 100 layers, providing a growth surface area of up to 85,000 cm². They offer a monolayer-like growth environment that is familiar to labs accustomed to traditional flask culture. However, scaling up can be labor-intensive.

Bioreactor Type	Drive Mechanism	Key Advantage	Primary Limitation
Stirred-Tank	Mechanical impeller	High scalability and uniform mixing	High shear stress from impeller
Rocking-Motion	Mechanical rocking	Low shear and efficient gas exchange	Limited scalability compared to STRs
Hollow Fiber	Hydraulic perfusion	High surface area in a compact footprint	High consumable costs
Fixed-Bed	Hydraulic perfusion	Protection from hydrodynamic shear	Potential nutrient gradients
Parallel Plate	Hydraulic perfusion	Familiar monolayer growth environment	Labor-intensive setup for large scale

Key Operational Factors in Bioreactor Systems

Achieving successful MSC (mesenchymal stem cell) expansion in bioreactors hinges on carefully managing several interconnected factors. Among these, oxygen and nutrient delivery and shear stress management play a central role, shaping the design and operation of bioreactor systems.

Oxygen and Nutrient Delivery

MSCs have an oxygen consumption rate of 90–300 fmol cell⁻¹h⁻¹. In three-dimensional cultures, oxygen can only diffuse about 100–150 µm into the cell mass, which limits spheroid sizes to roughly 300 µm in diameter. This restriction is crucial in preventing the formation of necrotic cores. Florian Petry and Denise Salzig from the Institute of Bioprocess Engineering and Pharmaceutical Technology highlight this limitation:

The diffusive distance of oxygen in stem cell spheroids is 100–150 µm, which limits the spheroid size to ∼300 µm.

Interestingly, lactate buildup often poses a more significant challenge to cell growth than oxygen or glucose depletion. As MSCs metabolize nutrients, lactate accumulates within dense cultures and spheroids, creating gradients that inhibit growth more strongly than moderate oxygen or glucose shortages.

To overcome these challenges, some bioreactors incorporate gas-permeable walls made from materials like PDMS (polydimethylsiloxane). This design allows oxygen to diffuse radially, reducing the reliance on medium flow and minimizing shear stress on cells. In packed-bed bioreactors, maintaining a perfusion flow velocity below 3 × 10⁻⁴ m/s is essential to preserve MSC growth rates.

Spheroid cultivation offers added benefits, such as increasing VEGF secretion by up to 100 times compared to monolayer cultures, significantly enhancing therapeutic potential. Proper oxygen delivery not only sustains cell viability but also boosts therapeutic effectiveness, making it a critical focus in clinical-scale MSC expansion. This process often begins with newborn stem cell preservation to ensure high-quality starting material.

Equally important is how mechanical forces are managed, as explored in the next section.

Shear Stress and Mechanical Stimulation

MSCs, lacking protective cell walls, are highly sensitive to mechanical forces. In stirred-tank bioreactors, shear forces can reach up to 2.5 N m⁻². While excessive shear can damage cells or trigger unwanted differentiation, controlled mechanical stimulation can enhance nutrient transport and even guide specific cell behaviors.

A study published in PLOS One by Osiecki and colleagues revealed that shear stress of 0.015 Pa can up-regulate osteogenic pathways in human bone marrow MSCs. This effect is closely tied to the actin cytoskeleton - the cell’s internal structural framework. Mechanical forces influence whether actin organizes into stress fibers or stays in a disorganized cortical structure. Sébastien Sart from Université Catholique de Louvain explains:

A tight control of the E-MSC microenvironment leading to adapted actin shape is the key towards efficient MSC differentiation on MCs.

For spheroid cultures, engineers use Kolmogorov's turbulence theory to fine-tune hydrodynamic forces. This ensures that turbulent eddies promote cell-cell collisions for spheroid formation without exceeding the adhesion forces that hold spheroids together. The target spheroid size for clinical applications - especially for liver vessel injections - ranges between 40 and 300 µm.

Between 2018 and 2019, researchers from Scinus Cell Expansion BV and Leiden University Medical Centre tested these principles. Using bone marrow-derived MSCs from five donors (average age 65.4 years), they expanded 20 million cells over six days in the Scinus bioreactor system. Final yields ranged from 222 million to 510 million cells. While bioreactor-expanded cells showed slightly lower population doublings (4.0) compared to flask cultures (5.0), they retained identical immunomodulatory functionality and tri-lineage differentiation capacity.

Scaling Up MSC Production with Bioreactors

Scalability and Cost Efficiency

Switching from traditional flask-based methods to industrial bioreactor systems has transformed the economics of manufacturing mesenchymal stem cells (MSCs). The manual nature of T-flask systems not only increases labor demands but also raises the risk of contamination. Enter the Quantum® Cell Expansion System by Terumo BCT, which highlights the benefits of automation. This platform provides a massive surface area of 21,000 cm², equivalent to about 120 T-175 flasks, while slashing open manipulation steps from 54,400 to just 133 compared to flask-based methods, according to research by Hanley and colleagues.

This shift to automated, closed bioreactor systems doesn’t just cut labor costs - it also reduces the need for high-grade cleanrooms, which are expensive to maintain. Single-use stirred-tank bioreactors, ranging in size from 0.5 L to 6,000 L, offer the flexibility to scale production in line with market demand, all without requiring multiple dedicated facilities.

Microcarriers further enhance efficiency by providing a growth surface up to 10 times greater than T-flasks, enabling high-yield production in a smaller space. For example, optimized 2 L stirred-tank bioreactors can deliver volumetric productivity of approximately 300–400 million cells per liter. This output comfortably meets the typical clinical dose requirement of 100–150 million cells per treatment in a single small-scale run.

These advancements not only reduce costs but also lay the groundwork for consistent, high-quality production - key elements explored in the next section on process consistency.

Maintaining Process Consistency

While advanced bioreactor designs streamline operations, maintaining consistent cell quality across production batches remains a significant challenge at scale. To address this, real-time monitoring systems continuously track critical parameters such as pH, dissolved oxygen, temperature, and metabolites. Glucose consumption and lactate production, in particular, serve as reliable indicators for determining the optimal harvest window.

Donor variability adds another layer of complexity, especially for autologous therapies, where cells from different donors may exhibit varying growth and adhesion behaviors. Although automated platforms help standardize conditions, manufacturers must validate their processes across multiple donor samples to ensure reliability. Closed systems like the CTS Rotea™ counterflow centrifugation system achieve cell recovery yields of 67% with viability above 96%, comparable to the 75% recovery rate of traditional open centrifugation, but with significantly lower contamination risks.

Another innovation, bead-to-bead transfer, simplifies the process by allowing cells to migrate between microcarriers. This eliminates the need for complex seed trains and detachment steps, while engineers maintain hydrodynamic conditions that ensure eddy sizes remain larger than the microcarriers. This approach minimizes shear stress, further protecting cell viability during scale-up.

Bioreactors in Clinical Applications and Future Directions

Selecting Bioreactors for Clinical Use

When it comes to producing clinical-grade mesenchymal stem cells (MSCs), the choice of bioreactor depends on several key factors: therapy type, production scale, and regulatory standards. For autologous therapies - where cells are derived from and used for the same individual - compact, automated systems like the CliniMACS Prodigy® or Cocoon® are ideal. These platforms handle both cell isolation and expansion while minimizing contamination risks. On the other hand, allogeneic therapies, which use cells from a single donor to treat multiple patients, require larger-scale systems. Stirred-tank bioreactors (ranging from 0.5 L to 6,000 L) or hollow-fiber systems like the Quantum® are better suited for these high-volume needs.

Regulatory compliance plays a big role in bioreactor selection. Clinical-grade systems must be closed and equipped with real-time monitoring for parameters like pH, oxygen levels, temperature, and metabolites. This level of automation reduces human error and ensures consistent results across batches. Additionally, the growing use of xeno-free media - such as human platelet lysate instead of fetal bovine serum - requires bioreactors that support these alternatives without compromising cell growth or attachment.

For anchorage-dependent MSCs, bioreactors must strike a balance between efficient nutrient delivery and gentle hydrodynamic conditions. In stirred-tank systems, maintaining the Kolmogorov eddy size above 50% of the microcarrier diameter helps protect cells from excessive shear stress. Hollow-fiber bioreactors, on the other hand, naturally offer low-shear environments and continuous media exchange, making them a strong option for these sensitive cells.

These considerations are critical for scaling up and ensuring the success of MSC-based therapies, underscoring the importance of bioreactor design in advancing regenerative medicine.

Advancements in Bioreactor Technology

Recent innovations in bioreactor technology are addressing clinical demands for compact systems, automation, and compliance with stringent regulations. A study published in BMC Biotechnology in January 2026 showcased a fully integrated platform for manufacturing adipose-derived MSCs. Using a 2 L Sartorius Univessel stirred-tank bioreactor with Synthemax II-coated microcarriers, researchers achieved impressive volumetric productivity of 300–400 million cells per liter. The downstream process was managed by the CTS Rotea counterflow centrifugation system, which maintained a closed system and delivered over 96% cell viability.

A major breakthrough in MSC cultivation is the use of spheroid-based culture. By growing MSCs as three-dimensional spheroids instead of traditional flat monolayers, researchers can better mimic the cells' natural environment. This approach delays cellular aging and boosts therapeutic effectiveness. For example, spheroid cultures have been shown to increase vascular endothelial growth factor (VEGF) secretion by up to 100 times compared to 2D cultures. However, there’s a catch: oxygen diffusion limits spheroid size to roughly 300 µm, as larger sizes can lead to necrotic cores due to insufficient mass transfer.

Another exciting development is bead-to-bead transfer technology. This method allows cells to migrate from used microcarriers to fresh ones without requiring enzymatic detachment. By eliminating complex seed trains, this approach speeds up production and simplifies scale-up. Coupled with real-time metabolite monitoring, manufacturers can now trigger critical steps like passaging and harvesting based on precise biological markers instead of fixed schedules. These "smart" workflows are paving the way for more efficient and higher-quality MSC production.

Conclusion

Bioreactor systems are reshaping how mesenchymal stem cell (MSC) therapies transition from research labs to real-world clinical applications. The conventional 2D flask methods simply can't keep up with the demand for clinical-grade MSCs, where each dose requires a staggering 100 to 150 million cells. Scaling this manually is not only inefficient but also incredibly labor-intensive. Bioreactors address this issue by offering controlled, scalable environments that ensure the quality needed for safe and effective treatments.

Modern bioreactor technology brings unmatched efficiency and consistency to the table. Automated systems like the Quantum® platform minimize manual handling, significantly reducing the risks of contamination and cutting operational costs. Stirred-tank bioreactors, for instance, can reach cell densities of 400,000 to 500,000 cells per milliliter, with productivity levels hitting 300 to 400 million cells per liter in optimized setups. These advancements are key to making MSC therapies viable on a clinical scale.

What sets bioreactors apart is their ability to replicate the natural 3D environments where cells thrive. By closely mimicking these conditions, bioreactors help maintain MSC potency and functionality. With precise control over factors like oxygen levels, nutrient delivery, and mechanical forces, these systems ensure that cells retain their identity and functional characteristics throughout the expansion process. This level of precision is critical for meeting Good Manufacturing Practice (GMP) standards and gaining regulatory approval.

As regulatory requirements evolve, bioreactor systems continue to advance, incorporating automation, xeno-free media, and real-time monitoring. Experts note that using whole cells as active pharmaceutical ingredients represents a groundbreaking shift in medicine. Bioreactor technology makes this shift feasible and scalable, turning the promise of regenerative medicine into a clinical reality.

For families banking stem cells with Americord Registry, these technological advancements enhance the therapeutic potential of stored cells. These innovations ensure that preserved cells are well-positioned for future regenerative treatments, offering a brighter outlook for emerging therapies.

FAQs

How do manufacturers choose the right bioreactor for autologous vs. allogeneic MSC therapies?

Manufacturers select bioreactors based on the specific therapy and production requirements. For autologous therapies, which use cells from an individual patient, smaller bioreactors are ideal. These systems focus on maintaining precise control to cater to the personalized conditions needed for each patient. On the other hand, allogeneic therapies, which rely on donor cells to treat multiple patients, require larger-scale systems. Stirred-tank bioreactors are commonly used here, as they are designed to ensure both consistency and efficiency in production. The design and scalability of the bioreactor play a key role in preserving cell quality while meeting production demands.

How do bioreactors prevent MSC damage from shear stress while still mixing well?

Bioreactors reduce the risk of damaging mesenchymal stem cells (MSCs) from shear stress by incorporating low-shear designs and carefully tailored impeller configurations. These design elements promote efficient mixing without generating excessive shear forces, which is crucial for maintaining the cells' viability and functionality.

What quality tests ensure bioreactor-expanded MSCs stay potent and consistent?

Quality tests for bioreactor-expanded mesenchymal stem cells (MSCs) focus on evaluating their viability, identity, and functionality. This involves confirming the expression of specific surface markers like CD73, CD90, and CD105, as well as assessing their ability to differentiate into osteogenic, chondrogenic, and adipogenic lineages. Additionally, their immunomodulatory properties are examined to ensure they meet therapeutic standards. Potency assays are also performed to confirm that MSCs retain their therapeutic roles, such as aiding in tissue repair or modulating the immune response. These rigorous tests are critical for delivering consistent, safe, and effective MSC-based treatments.